Epoetin Beta
drugOn this page
Also known as BM 06.019EPOCHEpoetina betaEpoetine betaNeorecormonNeorecormon 1000Neorecormon 10000Neorecormon 2000Neorecormon 20000Neorecormon 3000Neorecormon 30000Neorecormon 4000Neorecormon 500Neorecormon 5000Neorecormon 6000Recormon 1000Recormon 10000Recormon 2000Recormon 5000
Summary
Epoetin Beta (CHEMBL2109092) is an approved protein (ATC B03XA01); indicated across 49 conditions including anemia and chronic kidney disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: B03XA01
- Indications: 49 conditions
- Clinical trials: 44
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109092 |
| Name | Epoetin Beta |
| Type | Protein |
| Max phase | 4 |
| ATC | B03XA01 |
Also known as: BM 06.019, EPOCH, Epoetin beta, Epoetina beta, Epoetine beta, Neorecormon, Neorecormon 1000, Neorecormon 10000, Neorecormon 2000, Neorecormon 20000, Neorecormon 3000, Neorecormon 30000
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
49 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| myelodysplastic syndrome | 3 | MONDO:0018881 | EFO:0000198 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| optic neuritis | 3 | MONDO:0005885 | EFO:0007405 |
| acute kidney injury | 3 | MONDO:0002492 | HP:0001919 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| cervical carcinoma | 3 | MONDO:0005131 | EFO:0001061 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| hip fracture | 3 | MONDO:0005327 | EFO:0003964 |
| chronic hepatitis C virus infection | 3 | MONDO:0005354 | EFO:0004220 |
| scoliosis | 3 | MONDO:0005392 | EFO:0004273 |
| perinatal asphyxia | 3 | MONDO:0006663 | EFO:1000824 |
| optic nerve disorder | 3 | MONDO:0002135 | MONDO:0002135 |
| brain ischemia | 3 | MONDO:0005299 | MONDO:0005299 |
| Foster-Kennedy syndrome | 3 | MONDO:0001998 | EFO:1001330 |
| acute myocardial infarction | 3 | MONDO:0004781 | EFO:0008583 |
| graft versus host disease | 3 | MONDO:0013730 | EFO:0004599 |
| neoplasm | 3 | MONDO:0005070 | MONDO:0004992 |
| lichen planus, oral | 3 | MONDO:0043923 | EFO:0008517 |
| spinal cord injury | 3 | MONDO:0043797 | MONDO:0043797 |
| injury | 2 | MONDO:0021178 | EFO:0000546 |
| mood disorder | 2 | MONDO:0005371 | EFO:0004247 |
| myocardial ischemia | 2 | MONDO:0024644 | EFO:1001375 |
| malaria | 2 | MONDO:0005136 | EFO:0001068 |
| cerebral palsy | 2 | MONDO:0006497 | EFO:1000632 |
| subarachnoid hemorrhage | 2 | MONDO:0005099 | EFO:0000713 |
| Hodgkins lymphoma | 2 | MONDO:0004952 | EFO:0000183 |
| ischemia reperfusion injury | 2 | MONDO:0005203 | EFO:0002687 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| peritoneal neoplasm | 2 | MONDO:0006901 | EFO:1001100 |
| chronic myelomonocytic leukemia | 2 | MONDO:0020311 | EFO:1001779 |
| kidney failure | 2 | MONDO:0001106 | EFO:1002048 |
| fallopian tube neoplasm | 2 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 2 | MONDO:0008170 | MONDO:0008170 |
| brain injury | 2 | MONDO:0043510 | MONDO:0043510 |
| anterior ischemic optic neuropathy | 2 | MONDO:0006649 | EFO:1000809 |
| multiple sclerosis | 2 | MONDO:0005301 | MONDO:0005301 |
| necrotizing enterocolitis | 1 | MONDO:0005313 | EFO:0003928 |
| optic atrophy | 1 | MONDO:0003608 | MONDO:0003608 |
| stroke disorder | 1 | MONDO:0005098 | EFO:0000712 |
| amyotrophic lateral sclerosis | 1 | MONDO:0004976 | MONDO:0004976 |
| Parkinson disease | 1 | MONDO:0005180 | MONDO:0005180 |
| autoimmune hepatitis | 0 | MONDO:0016264 | EFO:0005676 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 44.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 14 |
| PHASE2 | 13 |
| PHASE3 | 11 |
| Not specified | 4 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00046969 | PHASE4 | COMPLETED | Epoetin Beta in Treating Anemia in Patients With Cervical Cancer |
| NCT00157300 | PHASE4 | COMPLETED | PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation |
| NCT00396435 | PHASE4 | COMPLETED | Correction of Anaemia and Progression of Renal Failure on Transplanted Patients |
| NCT00526448 | PHASE4 | UNKNOWN | Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients |
| NCT00773513 | PHASE4 | COMPLETED | A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) |
| NCT00776425 | PHASE4 | COMPLETED | A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies |
| NCT02145026 | PHASE4 | COMPLETED | A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) |
| NCT02554942 | PHASE4 | COMPLETED | A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors |
| NCT02564094 | PHASE4 | COMPLETED | A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies |
| NCT02569515 | PHASE4 | COMPLETED | A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia |
| NCT02608060 | PHASE4 | TERMINATED | A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B |
| NCT02624141 | PHASE4 | TERMINATED | A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy |
| NCT02876211 | PHASE4 | TERMINATED | Paricalcitol Improves Anemia of Inflammation |
| NCT03658876 | PHASE4 | COMPLETED | Predictors of Response to Iron and Erythropoietin Stimulating Agents |
| NCT00053768 | PHASE3 | COMPLETED | Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin’s Lymphoma |
| NCT00060385 | PHASE2/PHASE3 | TERMINATED | Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin’s Lymphoma |
| NCT00090753 | PHASE3 | COMPLETED | A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia |
| NCT00354341 | PHASE3 | COMPLETED | (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy |
| NCT00442793 | PHASE3 | COMPLETED | A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease. |
| NCT00482716 | PHASE3 | UNKNOWN | Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer |
| NCT00492427 | PHASE3 | COMPLETED | Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta) |
| NCT00628043 | PHASE3 | COMPLETED | Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients |
| NCT00717821 | PHASE3 | COMPLETED | A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis. |
| NCT00773331 | PHASE3 | COMPLETED | A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia. |
| NCT01364402 | PHASE3 | UNKNOWN | Prevention of Contrast Induced Nephropathy by Erythropoietin |
| NCT02827266 | PHASE3 | COMPLETED | A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis |
| NCT00001379 | PHASE2 | COMPLETED | Treatment and Natural History Study of Lymphomatoid Granulomatosis |
| NCT00001563 | PHASE2 | COMPLETED | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma |
| NCT00006436 | PHASE2 | COMPLETED | EPOCH and Rituximab to Treat Non-Hodgkin’s Lymphoma in Patients With HIV Infection |
| NCT00006669 | PHASE2 | WITHDRAWN | Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin’s Lymphoma |
| NCT00069238 | PHASE2 | COMPLETED | Campath-1H and EPOCH to Treat Non-Hodgkin’s T- and NK-Cell Lymphomas |
| NCT00114738 | PHASE2 | COMPLETED | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma |
| NCT00273767 | PHASE2 | COMPLETED | Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB |
| NCT00559195 | PHASE2 | COMPLETED | Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors |
| NCT00983944 | PHASE2 | WITHDRAWN | Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma |
| NCT01015352 | PHASE2 | COMPLETED | Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) |
| NCT01030900 | PHASE2 | COMPLETED | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas |
| NCT01718379 | PHASE2 | COMPLETED | Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. |
| NCT02761642 | PHASE2 | COMPLETED | A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy |
| NCT01085552 | PHASE1 | COMPLETED | Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia, chronic kidney disease, myelodysplastic syndrome, myocardial infarction, optic neuritis, acute kidney injury, diffuse large B-cell lymphoma, cervical carcinoma, lymphoma, hip fracture, chronic hepatitis C virus infection, scoliosis, perinatal asphyxia, optic nerve disorder, brain ischemia, acute myocardial infarction, graft versus host disease, neoplasm, lichen planus, oral, spinal cord injury